Hereditary Angioedema

Optimizing Screening and Management of the Patient with Hereditary Angioedema: A Primer for Primary Care Practice

Print This Post Print This Post

CME Information


expired

Learning Objectives

After participating in this educational activity, participants should be better able to:

  1. Apply available screening and diagnostic tools to promptly differentiate between clinical presentations and symptoms of HAE to accurately identify patients with HAE
  2. Customize treatment utilizing consensus algorithms, published clinical evidence, and new therapeutic options for acute attacks of HAE
  3. Implement strategies to ensure “attack vigilance” by treating HAE symptoms early and employ prophylactic strategies in patients with recognizable prodromal symptoms

 

Introduction

Hereditary angioedema (HAE) affects approximately 6,000 to 10,000 individuals in the United States of all races and ethnicities. The disease exacts a considerable toll in terms of human pain and suffering, impaired quality of life, and cost to patients and the healthcare system. Reported rates of mortality range from 30% to 50% with asphyxiation from laryngeal edema being a major contributing factor. Patients suffer episodic attacks of painful edema of the face, tongue, extremities, genitals, larynx, and bowels as well as nausea, vomiting, and diarrhea, which can last for 2 to 5 days before resolving. Acute attacks of HAE can result in disfiguring edema, disruptions to daily living, significantly decreased quality of life, unnecessary gastrointestinal surgery, and potential loss of life from a severe attack of laryngeal edema.

 

This activity has expired and is no longer available for CME; however, we hope you still enjoy the education.